A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 94, Issue , 2014, Pages 65-70

  Simiele, Marco ^a   Baietto, Lorena ^a   Audino, Alessio ^a   Sciandra, Mauro ^a   Bonora, Stefano ^a   Di Perri, Giovanni ^a   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

HIV; HPLC MS; Maraviroc; Plasma; Therapeutic drug monitoring

Indexed keywords

HIV; HPLC-MS; MARAVIROC; PLASMA; THERAPEUTIC DRUG MONITORING;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANES; HIV INFECTIONS; HUMANS; LIMIT OF DETECTION; MASS SPECTROMETRY; RECEPTORS, CCR5; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; TRIAZOLES;

EID: 84894192639     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.01.031     Document Type: Article

References (53)

1. Taiwo B.O., Hicks C.B. Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance. AIDS Read 2007, 17:151-156. 159-161.
2. Cohen C.J., Molina J.M., Cassetti I., Chetchotisakd P., Lazzarin A., Orkin C., Rhame F., Stellbrink H.J., Li T., Crauwels H., Rimsky L., Vanveggel S., Williams P., Boven K. Week 96 efficacy and safety of rilpivirine in treatment-naive HIV-1 patients in two Phase III randomized trials. AIDS 2012, 27:939-950.
3. Hughes C.A., Robinson L., Tseng A., MacArthur.R.D. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin. Pharmacother. 2009, 10:2445-2466.
4. Wilkin A., Pozniak A.L., Morales-Ramirez J., Lupo S.H., Santoscoy M., Grinsztejn B., Ruxrungtham K., Rimsky L.T., Vanveggel S., Boven K. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res. Hum. Retroviruses 2011, 28:437-446.
5. Correll T., Klibanov O.M. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy 2008, 28:90-101.
6. Markowitz M., Nguyen B.Y., Gotuzzo E., Mendo F., Ratanasuwan W., Kovacs C., Prada G., Morales-Ramirez J.O., Crumpacker C.S., Isaacs R.D., Gilde L.R., Wan H., Miller M.D., Wenning L.A., Teppler H. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 2007, 46:125-133.
7. Bredeek U.F., Harbour M.J. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1. Eur. J. Med. Res. 2007, 12:427-434.
8. Dhami H., Fritz C.E., Gankin B., Pak S.H., Yi W., Seya M.J., Raffa R.B., Nagar S. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. J. Clin. Pharm. Ther. 2009, 34:147-160.
9. Este J.A., Telenti A. HIV entry inhibitors. Lancet 2007, 370:81-88.
10. Fatkenheuer G., Nelson M., Lazzarin A., Konourina I., Hoepelman A.I., Lampiris H., Hirschel B., Tebas P., Raffi F., Trottier B., Bellos N., Saag M., Cooper D.A., Westby M., Tawadrous M., Sullivan J.F., Ridgway C., Dunne M.W., Felstead S., Mayer H., van der Ryst E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 2008, 359:1442-1455.
11. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., Saag M.S., Goebel F.D., Rockstroh J.K., Dezube B.J., Jenkins T.M., Medhurst C., Sullivan J.F., Ridgway C., Abel S., James I.T., Youle M., van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 2005, 11:1170-1172.
12. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., Nadler J., Clotet B., Karlsson A., Wohlfeiler M., Montana J.B., McHale M., Sullivan J., Ridgway C., Felstead S., Dunne M.W., van der Ryst E., Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008, 359:1429-1441.
13. Lorenzen T., Stoehr A., Walther I., Plettenberg A. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1. Eur. J. Med. Res. 2007, 12:419-425.
14. MacArthur R.D., Novak R.M. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 2008, 47:236-241.
15. Yost R., Pasquale T.R., Sahloff E.G. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am. J. Health Syst. Pharm. 2009, 66:715-726.
16. Pfizer, in, 2008.
17. Hyland R., Dickins M., Collins C., Jones H., Jones B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br. J. Clin. Pharmacol. 2008, 66:498-507.
18. Abel S., Back D.J., Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir. Ther. 2009, 14:607-618.
19. Kaplan J.E., Benson C., Holmes K.H., Brooks J.T., Pau A., Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 2009, 58:1-207. quiz CE201-CE204.
20. Back D., Gibbons S., Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit. 2006, 28:468-473.
21. Back D., Gatti G., Fletcher C., Garaffo R., Haubrich R., Hoetelmans R., Kurowski M., Luber A., Merry C., Perno C.F. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002, 16(Suppl. 1):S5-S37.
22. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005, 6(Suppl. 2):1-61.
23. Gazzard B., Bernard A.J., Boffito M., Churchill D., Edwards S., Fisher N., Geretti A.M., Johnson M., Leen C., Peters B., Pozniak A., Ross J., Walsh J., Wilkins E., Youle M. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006, 7:487-503.
24. Siccardi M., D'Avolio A., Nozza S., Simiele M., Baietto L., Stefani F.R., Moss D., Kwan W.S., Castagna A., Lazzarin A., Calcagno A., Bonora S., Back D., Di Perri G., Owen A. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet. Genomics 2011, 20:759-765.
25. Brewer E., Felix T., Clarke P., Edgington A., Muirhead D. An LC-MS-MS method for quantitative determination of maraviroc (UK-427, 857) in human plasma, urine and cerebrospinal fluid. Biomed. Chromatogr. 2010, 24:1316-1323.
26. D'Avolio A., Simiele M., Baietto L., Siccardi M., Sciandra M., Patanella S., Bonora S., Di Perri G. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther. Drug Monit. 2010, 32:86-92.
27. Else L., Watson V., Tjia J., Hughes A., Siccardi M., Khoo S., Back D. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2010, 878:1455-1465.
28. Fayet A., Beguin A., Zanolari B., Cruchon S., Guignard N., Telenti A., Cavassini M., Gunthard H.F., Buclin T., Biollaz J., Rochat B., Decosterd L.A. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:1057-1069.
29. Martin J., Deslandes G., Dailly E., Renaud C., Reliquet V., Raffi F., Jolliet P. A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:3072-3082.
30. Notari S., Tommasi C., Nicastri E., Bellagamba R., Tempestilli M., Pucillo L.P., Narciso P., Ascenzi P. Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV. IUBMB Life 2009, 61:470-475.
31. Takahashi M., Hirano A., Okubo N., Kinoshita E., Nomura T., Kaneda T. Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations. J. Med. Invest. 2010, 57:245-250.
32. Guideline on Bioanalytical Method Validation European Medicines Agency 2011, Guideline on Bioanalytical Method Validation.
33. Guidance for Industry Bioanalytical Method Validation Food and Drug Administration 2001, Guidance for Industry Bioanalytical Method Validation.
34. Taylor P.J. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 2005, 38:328-334.
35. w.s.g.i. HIV Italian guideline, in, 2010.
36. D'Avolio A., Baietto L., Siccardi M., Sciandra M., Simiele M., Oddone V., Bonora S., Di Perri G. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther. Drug Monit. 2008, 30:662-669.
37. D'Avolio A., Sciandra M., Siccardi M., Baietto L., de Requena D.G., Bonora S., Di Perri G. A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 848:374-378.
38. D'Avolio A., Siccardi M., Sciandra M., Baietto L., Bonora S., Trentini L., Di Perri G. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 859:234-240.
39. D'Avolio A., Simiele M., De Francia S., Ariaudo A., Baietto L., Cusato J., Fava C., Saglio G., Di Carlo F., Di Perri G. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). J. Pharm. Biomed. Anal. 2011, 59:109-116.
40. D'Avolio A., Simiele M., Siccardi M., Baietto L., Sciandra M., Bonora S., Di Perri G. HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. J. Pharm. Biomed. Anal. 2010, 52:774-780.
41. D'Avolio A., Simiele M., Siccardi M., Baietto L., Sciandra M., Oddone V., Stefani F.R., Agati S., Cusato J., Bonora S., Di Perri G. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J. Pharm. Biomed. Anal. 2010, 54:779-788.
42. De Francia S., D'Avolio A., De Martino F., Pirro E., Baietto L., Siccardi M., Simiele M., Racca S., Saglio G., Di Carlo F., Di Perri G. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:1721-1726.
43. Baietto L., D'Avolio A., De Rosa F.G., Garazzino S., Michelazzo M., Ventimiglia G., Siccardi M., Simiele M., Sciandra M., Di Perri G. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Anal. Bioanal. Chem. 2009, 396:791-798.
44. Baietto L., D'Avolio A., De Rosa F.G., Garazzino S., Patanella S., Siccardi M., Sciandra M., Di Perri G. Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV. Ther. Drug Monit. 2009, 31:104-109.
45. Baietto L., D'Avolio A., Marra C., Simiele M., Cusato J., Pace S., Ariaudo A., De Rosa F.G., Di Perri G. Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. J. Antimicrob. Chemother. 2012, 67:2645-2649.
46. Baietto L., D'Avolio A., Ventimiglia G., De Rosa F.G., Siccardi M., Simiele M., Sciandra M., Di Perri G. Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. Antimicrob. Agents Chemother. 2010, 54:3408-3413.
47. D'Avolio A., De Nicolo A., Agnesod D., Simiele M., Mohamed Abdi A., Dilly Penchala S., Boglione L., Cariti G., Di Perri G. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. J. Pharm. Biomed. Anal. 2013, 78-79:217-223.
48. Madruga J.V., Cahn P., Grinsztejn B., Haubrich R., Lalezari J., Mills A., Pialoux G., Wilkin T., Peeters M., Vingerhoets J., de Smedt G., Leopold L., Trefiglio R., Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:29-38.
49. Baietto L., D'Avolio A., Pace S., Simiele M., Marra C., Ariaudo A., Di Perri G., De Rosa F.G. Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. J. Pharm. Biomed. Anal. 2013, 88:66-70.
50. D'Avolio A., Baietto L., De Rosa F.G., Garazzino S., Sciandra M., Siccardi M., Bonora S., Di Perri G. A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. Ther. Drug Monit. 2008, 30:90-94.
51. D'Avolio A., Peila E., Simiele M., Pensi D., Baietto L., Cusato J., Cinnirella G., De Rosa F., Di Perri G. Ultra performance liquid chromatography PDA method for determination of tigecycline in human plasma. Ther. Drug Monit. 2013, 35:853-858.
52. W. KKGT, in, 2009.
53. W. TDM Torino, in, 2009.